Citi analyst Yigal Nochomovitz raised the firm’s price target on Sarepta (SRPT) to $13 from $9 and keeps a Sell rating on the shares. The firm says yesterday’s “positive” Phase 1/2 interim data from SRP-1001 and SRP-1003 show initial clinical proof of concept of Sarepta’s TRiM platform’s optimization for tissue specificity.
Claim 55% Off TipRanks
New trading tool for SRPT bullsPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta price target raised to $25 from $20 at Morgan Stanley
- Midday Fly By: Merck to acquire Terns, Arm CPU launch applauded
- Sarepta initial siRNA data ‘thin and somewhat mixed,’ says Leerink
- Sarepta early DM1 data ‘appear promising,’ says Oppenheimer
- Sarepta announces first clinical data from pipeline targeting FSHD1, DM1